Medivation

Medivation Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. The Company's first compound is enzalutamide, an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell. Enzalutamide is used for the treatment of patients with metastatic castration-resistant prostate cancer and is being further developed* for earlier stages of prostate cancer, advanced breast cancer, and hepatocellular carcinoma.

Type
Subsidiary
Parent Company
Pfizer
HQ
San Francisco, US
Founded
2004
Medivation was founded in 2004 and is headquartered in San Francisco, US

Medivation Office Locations

Medivation has offices in San Francisco, Washington, Jersey and New York
San Francisco, US (HQ)
525 Market St

Medivation Financials and Metrics

Medivation Summary

Founding Date

2004
Medivation is a subsidiary of Pfizer

Medivation Financials

USDFY, 2013FY, 2014

EBIT

(22.2 m)281.8 m

Net Income

(42.6 m)276.5 m
USDFY, 2013FY, 2014FY, 2015

Cash

228.8 m502.7 m225.9 m

Inventories

18 m12.3 m15.9 m

Current Assets

354 m721.9 m634.2 m

PP&E

17 m41.2 m58.1 m
USDFY, 2013FY, 2014FY, 2015

Net Income

(42.6 m)276.5 m244.7 m

Inventories

(4 m)301 k(4.6 m)

Accounts Payable

1.7 m

Cash From Operating Activities

(68.2 m)273.9 m
Show all financial metrics

Traffic Overview of Medivation

Medivation Company Life and Culture

You may also be interested in